Peter J Nestor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5200887/publications.pdf

Version: 2024-02-01

161 161 16508
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	A Systematic Review of Apathy and Depression in Progressive Supranuclear Palsy. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 280-292.	1.2	12
2	Traumatic brain injury fast-forwards Alzheimer's pathology: evidence from amyloid positron emission tomorgraphy imaging. Journal of Neurology, 2022, 269, 873-884.	1.8	19
3	Support vector machine learning and diffusion-derived structural networks predict amyloid quantity and cognition in adults with Down's syndrome. Neurobiology of Aging, 2022, 115, 112-121.	1.5	2
4	Instant tissue field and magnetic susceptibility mapping from MRI raw phase using Laplacian enhanced deep neural networks. NeuroImage, 2022, 259, 119410.	2.1	12
5	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 614-628.	4.1	61
6	Measuring cerebral perfusion with $[11C]$ -PiB R1 in Down syndrome: associations with amyloid burden and longitudinal cognitive decline. Brain Communications, 2021, 3, fcaa198.	1.5	3
7	What's "up� Impaired Spatial Preposition Processing in Posterior Cortical Atrophy. Frontiers in Human Neuroscience, 2021, 15, 731104.	1.0	2
8	7T MR neurographyâ€ultrasound fusion for peripheral nerve imaging. Muscle and Nerve, 2020, 61, 521-526.	1.0	6
9	The upper cervical spinal cord in ALS assessed by cross-sectional and longitudinal 3T MRI. Scientific Reports, 2020, 10, 1783.	1.6	7
10	Sonographic and 3T-MRI-based evaluation of the tongue in ALS. NeuroImage: Clinical, 2020, 26, 102233.	1.4	11
11	A multiâ€contrast MRI approach to thalamus segmentation. Human Brain Mapping, 2020, 41, 2104-2120.	1.9	4
12	Prominent White Matter Involvement in Multiple System Atrophy of Cerebellar Type. Movement Disorders, 2020, 35, 816-824.	2.2	15
13	The concept of regularization: Resolving the problem of surface dyslexia in semantic variant primary progressive aphasia across different languages Neuropsychology, 2020, 34, 298-307.	1.0	3
14	Differential effects of Down's syndrome and Alzheimer's neuropathology on default mode connectivity. Human Brain Mapping, 2019, 40, 4551-4563.	1.9	36
15	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. Radiology, 2019, 293, 646-653.	3.6	20
16	The atrophy pattern in Alzheimer-related PPA is more widespread than that of the frontotemporal lobar degeneration associated variants. Neurolmage: Clinical, 2019, 24, 101994.	1.4	18
17	Delineating the topography of amyloid-associated cortical atrophy in Down syndrome. Neurobiology of Aging, 2019, 80, 196-202.	1.5	8
18	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 301-309.	1.2	30

#	Article	IF	CITATIONS
19	Toward <i>in vivo</i> determination of peripheral nervous system immune activity in amyotrophic lateral sclerosis. Muscle and Nerve, 2019, 59, 567-576.	1.0	21
20	Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deepâ€phenotyping case report. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 654-658.	1.2	13
21	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. Brain, 2018, 141, 1186-1200.	3.7	83
22	Prefrontal cortical thickness in motor neuron disease. NeuroImage: Clinical, 2018, 18, 648-655.	1.4	11
23	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	3.0	131
24	Automated assessment of FDC-PET for differential diagnosis in patients with neurodegenerative disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1557-1566.	3.3	35
25	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1546-1556.	3.3	24
26	Clinical utility of FDG-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508.	3.3	61
27	Differential involvement of forearm muscles in ALS does not relate to sonographic structural nerve alterations. Clinical Neurophysiology, 2018, 129, 1438-1443.	0.7	9
28	Peripheral nerve atrophy together with higher cerebrospinal fluid progranulin indicate axonal damage in amyotrophic lateral sclerosis. Muscle and Nerve, 2018, 57, 273-278.	1.0	17
29	P2â€455: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P894.	0.4	O
30	ICâ€Pâ€155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P131.	0.4	0
31	ICâ€Pâ€163: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P137.	0.4	0
32	F1â€04â€02: ASSOCIATION BETWEEN NEURAL NOVELTY RESPONSES AND CSF BIOMARKERS OF ALZHEIMER'S DISEASE: ANATOMICAL SPECIFICITY AND DEPENDENCE ON ATROPHY. Alzheimer's and Dementia, 2018, 14, P206.	0.4	0
33	F4â€08â€04: SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1396.	0.4	0
34	P1â€449: MAPPING AMYLOID DEPOSITION ON CORTICAL ATROPHY IN DOWN SYNDROME: A COMBINED BASELINE AND 2‥EAR LONGITUDINAL ANALYSIS. Alzheimer's and Dementia, 2018, 14, P487.	0.4	0
35	P2â€447: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P888.	0.4	О
36	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	1.2	26

#	Article	IF	CITATIONS
37	P1â€399: CORTICAL ATROPHY IN ADâ€RELATED PRIMARY PROGRESSIVE APHASIA AFFECTS THE ENTIRE LEFT HEMISPHERE LANGUAGE NETWORK. Alzheimer's and Dementia, 2018, 14, P455.	0.4	0
38	Significance of CSF NfL and tau in ALS. Journal of Neurology, 2018, 265, 2633-2645.	1.8	45
39	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1534-1545.	3.3	86
40	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1487-1496.	3.3	35
41	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain ¹⁸ Fâ€fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology. 2018. 25. 1201-1217.	1.7	153
42	Quantitative Susceptibility MRI to Detect Brain Iron in Amyotrophic Lateral Sclerosis. Radiology, 2018, 289, 195-203.	3.6	61
43	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1509-1525.	3.3	81
44	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1526-1533.	3.3	28
45	The European DTI Study on Dementia — A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. NeuroImage, 2017, 144, 305-308.	2.1	33
46	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
47	The Down syndrome brain in the presence and absence of fibrillar \hat{l}^2 -amyloidosis. Neurobiology of Aging, 2017, 53, 11-19.	1.5	50
48	Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline. Neurobiology of Aging, 2017, 56, 41-49.	1.5	109
49	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimer's Research and Therapy, 2017, 9, 27.	3.0	66
50	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
51	Semantic word category processing in semantic dementia and posterior cortical atrophy. Cortex, 2017, 93, 92-106.	1.1	20
52	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
53	Mutations in the vesicular trafficking protein annexin All are associated with amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9 , .	5.8	129
54	Beyond clinical syndromes in primary progressive aphasia. Neurology, 2017, 88, 2244-2245.	1.5	2

#	Article	IF	Citations
55	Can MRI Visual Assessment Differentiate the Variants of Primary-Progressive Aphasia?. American Journal of Neuroradiology, 2017, 38, 954-960.	1.2	25
56	Reply:. American Journal of Neuroradiology, 2017, 38, E64-E64.	1.2	0
57	Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. Scientific Reports, 2017, 7, 9529.	1.6	27
58	Data-driven classification of patients with primary progressive aphasia. Brain and Language, 2017, 174, 86-93.	0.8	49
59	[P2–074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. Alzheimer's and Dementia, 2017, 13, P634.	0.4	O
60	The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease. Brain, 2017, 140, 118-131.	3.7	154
61	[ICâ€Pâ€080]: USEFULNESS AND STABILITY OF MULTICENTER DIFFUSION TENSOR IMAGING AS AN EARLY MARKE FOR SUBJECTIVE COGNITIVE DECLINE AND AMNESTIC MILD COGNITIVE IMPAIRMENT: FIRST RESULTS FROM THE PROSPECTIVE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P66.	R 0.4	2
62	[P2â€"390]: LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT. Alzheimer's and Dementia, 2017, 13, P779.	0.4	1
63	[P3–393]: ROBUST AUTOMATED DETECTION OF SUBJECTIVE COGNITIVE DECLINE AND PRODROMAL ALZHEIMER'S DISEASE BASED ON MULTICENTER RESTINGâ€STATE FUNCTIONAL CONNECTIVITY: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1112.	0.4	O
64	[P1–122]: WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER's DISEASE, AND NEURAL NETWORKS. Alzheimer's and Dementia, 2017, 13, P287.	0.4	2
65	[P4–248]: QUALITY ASSURANCE IN DELCODE: A MULTIâ€CENTER NEUROIMAGING STUDY. Alzheimer's and Dementia, 2017, 13, P1372.	0.4	O
66	Dementia of the personality. Medical Journal of Australia, 2017, 207, 286-287.	0.8	0
67	Quantifying disease progression in amyotrophic lateral sclerosis using peripheral nerve sonography. Muscle and Nerve, 2016, 54, 391-397.	1.0	40
68	High-resolution characterisation of the aging brain using simultaneous quantitative susceptibility mapping (QSM) and R2* measurements at 7 T. Neurolmage, 2016, 138, 43-63.	2.1	101
69	Structural and diffusion imaging versus clinical assessment to monitor amyotrophic lateral sclerosis. NeuroImage: Clinical, 2016, 11, 408-414.	1.4	51
70	<i>In Vivo</i> MRI Mapping of Brain Iron Deposition across the Adult Lifespan. Journal of Neuroscience, 2016, 36, 364-374.	1.7	217
71	The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimer's and Dementia, 2016, 12, 538-545.	0.4	136
72	Bedside assessment of cognition. , 2016, , 105-112.		0

#	Article	IF	Citations
73	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment – A Multicenter DTI and Volumetry Study. Journal of Alzheimer's Disease, 2015, 48, 197-204.	1.2	56
74	SECT and MAST: new tests to assess grammatical abilities in primary progressive aphasia. Aphasiology, 2015, 29, 1135-1151.	1.4	12
75	Hereditary diffuse leukoencephalopathy with spheroids (HDLS) with a novel CSF1R mutation and spinal cord involvement. Journal of the Neurological Sciences, 2015, 358, 515-517.	0.3	12
76	Peripheral nerve ultrasound in amyotrophic lateral sclerosis phenotypes. Muscle and Nerve, 2015, 51, 669-675.	1.0	55
77	Diffusion tensor imaging in Alzheimer's disease: insights into the limbic-diencephalic network and methodological considerations. Frontiers in Aging Neuroscience, 2014, 6, 266.	1.7	96
78	Central white matter degeneration in bulbar- and limb-onset amyotrophic lateral sclerosis. Journal of Neurology, 2014, 261, 1961-1967.	1.8	30
79	Hippocampal degeneration in patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2014, 35, 2639-2645.	1.5	62
80	Comparing voxel-based iterative sensitivity and voxel-based morphometry to detect abnormalities in T2-weighted MRI. Neurolmage, 2014, 100, 379-384.	2.1	1
81	A New Fast Accurate Nonlinear Medical Image Registration Program Including Surface Preserving Regularization. IEEE Transactions on Medical Imaging, 2014, 33, 2118-2127.	5.4	16
82	Logopenic, mixed, or Alzheimer-related aphasia?. Neurology, 2014, 82, 1127-1131.	1.5	60
83	CADASIL presenting with a behavioural variant frontotemporal dementia phenotype. Journal of Clinical Neuroscience, 2014, 21, 165-167.	0.8	3
84	Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases. Brain, 2013, 136, 2253-2261.	3.7	60
85	The C9ORF72 expansion mutation is a common cause of ALS+/ \hat{a}^{*} FTD in Europe and has a single founder. European Journal of Human Genetics, 2013, 21, 102-108.	1.4	201
86	Degenerator tau/TDP-43: rise of the machines. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 945-945.	0.9	1
87	A Brief History of Voxel-Based Grey Matter Analysis in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 647-659.	1.2	27
88	In Vivo Quantitative Susceptibility Mapping (QSM) in Alzheimer's Disease. PLoS ONE, 2013, 8, e81093.	1.1	235
89	VBM with viscous fluid registration of gray matter segments in SPM. Frontiers in Aging Neuroscience, 2013, 5, 30.	1.7	5
90	The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H ₃ Receptor Antagonist in Patients with Mild to Moderate Alzheimer's Disease: A Preliminary Investigation. Current Alzheimer Research, 2013, 10, 240-251.	0.7	64

#	Article	IF	Citations
91	Abnormalities of connected speech in semantic dementia vs Alzheimer's disease. Aphasiology, 2012, 26, 847-866.	1.4	87
92	Abnormalities of connected speech in the non-semantic variants of primary progressive aphasia. Aphasiology, 2012, 26, 1219-1237.	1.4	38
93	<scp>EFNS</scp> task force: the use of neuroimaging in the diagnosis of dementia. European Journal of Neurology, 2012, 19, 1487-1501.	1.7	112
94	Reversal of abnormal eating and drinking behaviour in a frontotemporal lobar degeneration patient using low-dose topiramate: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 349-350.	0.9	18
95	The relationship of topographical memory performance to regional neurodegeneration in Alzheimer's disease. Frontiers in Aging Neuroscience, 2012, 4, 17.	1.7	47
96	Primary progressive aphasia. Neurology, 2012, 78, 1670-1677.	1.5	201
97	Diffusion Tensor Metrics as Biomarkers in Alzheimer's Disease. PLoS ONE, 2012, 7, e49072.	1.1	101
98	MRI detection of tissue pathology beyond atrophy in Alzheimer's disease: Introducing T2-VBM. Neurolmage, 2011, 56, 1946-1953.	2.1	28
99	Hippocampal dysfunction in patients with mild cognitive impairment: A functional neuroimaging study of a visuospatial paired associates learning task. Neuropsychologia, 2011, 49, 2060-2070.	0.7	142
100	Profiles of recent autobiographical memory retrieval in semantic dementia, behavioural-variant frontotemporal dementia, and Alzheimer's disease. Neuropsychologia, 2011, 49, 2694-2702.	0.7	178
101	Attenuation Correction Methods Suitable for Brain Imaging with a PET/MRI Scanner: A Comparison of Tissue Atlas and Template Attenuation Map Approaches. Journal of Nuclear Medicine, 2011, 52, 1142-1149.	2.8	74
102	Atrophy, hypometabolism and white matter abnormalities in semantic dementia tell a coherent story. Brain, 2011, 134, 2025-2035.	3.7	185
103	Magnetoencephalography of frontotemporal dementia: spatiotemporally localized changes during semantic decisions. Brain, 2011, 134, 2513-2522.	3.7	25
104	Clinical comparison of progressive aphasia associated with Alzheimer versus FTD-spectrum pathology. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 254-260.	0.9	25
105	Lost and Found: Bespoke Memory Testing for Alzheimer's Disease and Semantic Dementia. Journal of Alzheimer's Disease, 2010, 21, 1347-1365.	1.2	78
106	The Word Processing Deficit in Semantic Dementia: All Categories Are Equal, but Some Categories Are More Equal than Others. Journal of Cognitive Neuroscience, 2010, 22, 2027-2041.	1.1	84
107	Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain, 2010, 133, 300-306.	3.7	246
108	What the left and right anterior fusiform gyri tell us about semantic memory. Brain, 2010, 133, 3256-3268.	3.7	377

#	Article	IF	Citations
109	Absolute diffusivities define the landscape of white matter degeneration in Alzheimer's disease. Brain, 2010, 133, 529-539.	3.7	359
110	Dementia in Lewy body syndromes. Neurology, 2010, 74, 872-873.	1.5	1
111	How preserved is episodic memory in behavioral variant frontotemporal dementia?. Neurology, 2010, 74, 472-479.	1.5	180
112	Focal posterior cingulate atrophy in incipient Alzheimer's disease. Neurobiology of Aging, 2010, 31, 25-33.	1.5	135
113	Registration accuracy for VBM studies varies according to region and degenerative disease grouping. Neurolmage, 2010, 49, 2205-2215.	2.1	66
114	Disturbances of higher cerebral function. , 2010, , 4786-4795.		0
115	Understanding social dysfunction in the behavioural variant of frontotemporal dementia: the role of emotion and sarcasm processing. Brain, 2009, 132, 592-603.	3.7	219
116	Transient epileptic amnesia: regional brain atrophy and its relationship to memory deficits. Brain, 2009, 132, 357-368.	3.7	116
117	Combined magnetic resonance imaging and positron emission tomography brain imaging in behavioural variant frontotemporal degeneration: refining the clinical phenotype. Brain, 2009, 132, 2566-2578.	3.7	106
118	Atrophy patterns in histologic vs clinical groupings of frontotemporal lobar degeneration. Neurology, 2009, 72, 1653-1660.	1.5	96
119	Characteristics of abnormal eating behaviours in frontotemporal lobar degeneration: a cross-cultural survey. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1413-1414.	0.9	30
120	Determinants of survival in behavioral variant frontotemporal dementia. Neurology, 2009, 73, 1656-1661.	1.5	88
121	Outcome in subgroups of mild cognitive impairment (MCI) is highly predictable using a simple algorithm. Journal of Neurology, 2009, 256, 1500-1509.	1.8	84
122	Comparative Reliability of Total Intracranial Volume Estimation Methods and the Influence of Atrophy in a Longitudinal Semantic Dementia Cohort. Journal of Neuroimaging, 2009, 19, 37-46.	1.0	82
123	The impact of skull-stripping and radio-frequency bias correction on grey-matter segmentation for voxel-based morphometry. Neurolmage, 2008, 39, 1654-1665.	2.1	95
124	Impact of inconsistent resolution on VBM studies. NeuroImage, 2008, 40, 1711-1717.	2.1	13
125	Predicting Rapid Clinical Progression in Amnestic Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2008, 25, 170-177.	0.7	62
126	Measuring progression in frontotemporal dementia. Neurology, 2008, 70, 2046-2052.	1.5	56

#	Article	IF	CITATIONS
127	Memory Complaints in Mild Cognitive Impairment, Worried Well, and Semantic Dementia Patients. Alzheimer Disease and Associated Disorders, 2008, 22, 227-235.	0.6	34
128	The Lewy body, the hallucination, the atrophy and the physiology. Brain, 2007, 130, e81-e81.	3.7	7
129	Dopamine transporter brain imaging—can it improve the differential diagnosis of dementia with Lewy bodies?. Nature Clinical Practice Neurology, 2007, 3, 602-603.	2.7	3
130	Behavioural variant Frontotemporal Dementia: Not all it seems?. Neurocase, 2007, 13, 237-247.	0.2	51
131	Nuclear imaging can predict pathologic diagnosis in progressive nonfluent aphasia. Neurology, 2007, 68, 238-239.	1.5	50
132	Don't forget cortical Lewy bodies. Journal of Clinical Neuroscience, 2007, 14, 296.	0.8	1
133	Focal cortical presentations of Alzheimer's disease. Brain, 2007, 130, 2636-2645.	3.7	510
134	Where do you know what you know? The representation of semantic knowledge in the human brain. Nature Reviews Neuroscience, 2007, 8, 976-987.	4.9	2,168
135	Semantic dementia and fluent primary progressive aphasia: two sides of the same coin?. Brain, 2006, 129, 3066-3080.	3.7	208
136	Declarative memory impairments in Alzheimer's disease and semantic dementia. NeuroImage, 2006, 30, 1010-1020.	2.1	343
137	Mild cognitive impairment: applicability of research criteria in a memory clinic and characterization of cognitive profile. Psychological Medicine, 2006, 36, 507-515.	2.7	112
138	Regional cerebral blood flow change in a case of Alzheimer's disease with musical hallucinations. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 236-239.	1.8	24
139	Clinical, imaging and pathological correlates of a hereditary deficit in verb and action processing. Brain, 2006, 129, 321-332.	3.7	116
140	Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology, 2006, 66, 935-937.	1.5	67
141	Methylphenidate ( Ritalin') can Ameliorate Abnormal Risk-Taking Behavior in the Frontal Variant of Frontotemporal Dementia. Neuropsychopharmacology, 2006, 31, 651-658.	2.8	123
142	Neural correlates of semantic and behavioural deficits in frontotemporal dementia. NeuroImage, 2005, 24, 1042-1051.	2.1	166
143	DISORDERS OF MEMORY., 2004, , 43-57.		0
144	Similar early clinical presentations in familial and non-familial frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1743-1745.	0.9	25

#	Article	IF	Citations
145	Advances in the early detection of Alzheimer's disease. Nature Medicine, 2004, 10, S34-S41.	15.2	401
146	Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology, 2004, 172, 400-408.	1.5	185
147	Pseudo-neglect in Huntington's disease correlates with decreased angular gyrus density. NeuroReport, 2004, 15, 1061-1064.	0.6	12
148	Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Annals of Neurology, 2003, 54, 343-351.	2.8	369
149	Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's) Tj ETQq1	1 0. 78431	4 ₁₉ 8T /Ove
150	The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's) Tj ETQq0 0 0	rgBT/Ove	rlqgk 10 Tf !
151	A Case of Unilateral Neglect in Huntington's Disease. Neurocase, 2003, 9, 261-273.	0.2	14
152	Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula. Brain, 2003, 126, 2406-2418.	3.7	299
153	Advances in early diagnosis and differentiation of the dementias. , 2003, , 262-288.		0
154	Memory consolidation and the hippocampus: further evidence from studies of autobiographical memory in semantic dementia and frontal variant frontotemporal dementia. Neuropsychologia, 2002, 40, 633-654.	0.7	107
155	Non-Alzheimer Dementias. Seminars in Neurology, 2000, 20, 439-446.	0.5	22
156	Proximal myotonic myopathy: a report of a kindred. Journal of Clinical Neuroscience, 1998, 5, 218-220.	0.8	1
157	Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Medical Journal of Australia, 1996, 164, 659-662.	0.8	138
158	Vitamin B 12 myeloneuropathy precipitated by nitrous oxide anaesthesia. Medical Journal of Australia, 1996, 165, 174-174.	0.8	11
159	Neuroimaging and other investigative findings. , 0, , 134-160.		2